Research Peptide Dosing Protocols: What Published Studies Actually Used

The Gap Between Animal Studies and Human Research

Here's something that surprises a lot of people when they first dig into the peptide literature: the doses used in published studies are often very different from what circulates in online communities. That gap isn't random — it reflects real differences in how scientists design experiments versus how substances eventually get used in the real world. Understanding what the published data actually shows is the first step toward interpreting any peptide research intelligently.

This article walks through the dosing data from published animal and human studies across several commonly researched peptides, explains how researchers convert doses between species, and presents the actual numbers used in controlled experiments. None of this constitutes medical advice or a dosing recommendation. It's a research education resource — a map of the existing literature so you can read it yourself with enough context to understand what you're looking at.

There's also a more practical point worth making upfront: reading dose data from animal studies without understanding species conversion methodology leads to systematic errors. Sometimes those errors result in over-estimating the appropriate human-equivalent amount; sometimes they underestimate it. The Nair and Jacob framework published in 2016 provides the tools to avoid those errors — which is why we're starting there.

Why Dose Conversion Matters: The Allometric Scaling Framework

Before looking at individual peptides, it helps to understand how researchers approach the animal-to-human dose conversion problem. Anroop Nair and Shery Jacob tackled this directly in a 2016 review published in the Journal of Basic and Clinical Pharmacy. Their paper — which has become a standard reference in pharmaceutical research — laid out what's called allometric scaling: the method the FDA uses to derive a Maximum Recommended Starting Dose for human clinical trials from animal safety data.

The core insight is simple but easy to overlook: you cannot just multiply an animal dose by the weight difference between a rat and a human. Larger animals have slower metabolic rates. Physiological time moves differently across species. A rat's liver processes compounds at a rate roughly six times faster per kilogram of body weight than a human liver does. Failing to account for this leads directly to systematic overestimation of what a human-equivalent dose would be.

Nair and Jacob's preferred conversion method uses body surface area normalization via what they call Km factors — a correction coefficient derived from each species' weight-to-surface-area ratio. The formula looks like this: Human Equivalent Dose (mg/kg) = Animal dose (mg/kg) × (Animal Km ÷ Human Km).

For a standard 150-gram rat, the Km is approximately 6. For a 60 kg human, it's 37. That gives a conversion factor of roughly 0.162 — meaning a rat dose of 10 mg/kg translates to an estimated human equivalent of about 1.6 mg/kg, not 10. That's a more than six-fold difference. This ratio is why you see such dramatic discrepancies between animal doses and projected human doses in peptide research. The commonly cited Km values for research species are: mouse (20 g) = 3; rat (150 g) = 6; monkey (3 kg) = 12; dog (10 kg) = 20; human (60 kg) = 37.

The FDA's own guidance for estimating maximum recommended starting doses for first-in-human trials uses this body surface area approach. It's not a theoretical exercise — it's the regulatory standard.

BPC-157: What Animal Studies Used

BPC-157 has probably the richest preclinical dataset of any research peptide. Across dozens of published studies — primarily from Sikiric's group at the University of Zagreb — the consistent finding is that BPC-157 produces measurable effects at remarkably low doses in animal models.

In musculoskeletal models (transected Achilles tendon, medial collateral ligament injury, bone healing), the typical animal dose has been 10 µg/kg administered intraperitoneally once daily. Some studies have demonstrated effects at doses as low as 10 ng/kg — three orders of magnitude lower — and even 10 pg/kg in certain model contexts. This extraordinary dose range without apparent toxicity is one of the more unusual features of the BPC-157 preclinical literature. No lethal dose has been identified in rodent studies even at doses approaching 20 mg/kg.

For gut and fistula healing models, Beck and colleagues published work in the International Journal of Colorectal Disease (2014) using both intraperitoneal and oral routes at 10 µg/kg and 10 ng/kg daily for 28-day periods. BPC-157 accelerated healing of colonic and skin defects across both dose levels — which is notable, because the nanogram dose wasn't dramatically less effective than the microgram dose in those gut models. The wide effective dose range is one of BPC-157's recurring experimental characteristics.

A pharmacokinetic modeling study, using beagle dogs and rats, proposed a putative human dose of 200 µg per person per day by working backward from body surface area scaling. The researchers then used this 200 µg/day working assumption to determine equivalent animal doses: approximately 20 µg/kg in rats and 6 µg/kg in dogs. These were then used in the PK study itself. If you apply simple weight-based scaling from the common 10 µg/kg rat dose to a 70 kg human, you'd arrive at 700 µg/day. Applying Nair and Jacob's allometric correction brings that estimate down substantially. Neither figure has been validated in controlled human trials.

For researchers exploring BPC-157 in vitro or in animal models, BPC-157 5mg and BPC-157 10mg vials represent the two most common research quantities. Understanding that effective animal doses range from picogram to microgram per kilogram across different model types is important context for experimental design.

CJC-1295: The Human Pharmacokinetic Data

CJC-1295 is one of the few research peptides that has genuine human dose data from a controlled clinical trial — which makes Teichman et al.'s 2006 paper in the Journal of Clinical Endocrinology & Metabolism the most important citation in this area, and worth understanding in detail.

Teichman's group (Teichman S.L., Neale A., Lawrence B., Gagnon C., Castaigne J.P., Frohman L.A.) administered single subcutaneous doses of CJC-1295 to healthy adults aged 21–61 years, using ascending doses in a dose-escalation design. At 30 µg/kg and 60 µg/kg, they observed dose-dependent increases in mean plasma GH concentrations of 2- to 10-fold, sustained for six or more days. That persistence — GH elevation lasting days after a single injection — is entirely due to CJC-1295's DAC (Drug Affinity Complex) modification, which allows it to covalently bind albumin in the bloodstream and achieve a half-life of 5.8 to 8.1 days.

IGF-1 followed a similar sustained pattern, increasing 1.5- to 3-fold and remaining elevated for 9–11 days after a single injection. After multiple doses administered weekly or biweekly, IGF-1 remained above baseline for up to 28 days — evidence of a cumulative effect from repeated dosing. No serious adverse reactions were reported at any dose in the study.

These are real numbers from a real human trial. They tell you something precise about the pharmacokinetic profile of CJC-1295 at those specific doses and routes — though that trial was designed to characterize pharmacokinetics, not to optimize outcomes for any particular research application.

An important nuance: CJC-1295 without DAC (also called Modified GRF 1-29, or Mod GRF 1-29) has a dramatically shorter half-life — roughly 15–30 minutes — because it lacks the albumin-binding modification. Researchers working with CJC-1295 No DAC / Mod GRF are working with a compound whose pharmacokinetics bear almost no resemblance to what Teichman studied. The Teichman 2006 data applies specifically to the DAC-modified version. This distinction matters when reading dose-response literature.

Ipamorelin: PK/PD Modeling Data from Healthy Volunteers

Ipamorelin's human pharmacology was characterized in a pharmacokinetic/pharmacodynamic modeling study using a dose-escalation design in healthy male subjects. Five IV infusion rates were tested: 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg, each administered over 15-minute infusions, with eight subjects at each dose level. The results provided detailed population PK/PD characterization that remains the most comprehensive human data on ipamorelin.

The terminal half-life was approximately 2 hours, with a clearance of 0.078 L/h/kg and a volume of distribution of 0.22 L/kg at steady state — PK parameters showing dose-proportionality across the range tested. GH stimulation followed predictable pharmacodynamics: a single episode of release peaking at about 0.67 hours (40 minutes) post-infusion, then declining exponentially to negligible concentrations at all dose levels tested.

The SC50 — the ipamorelin concentration required for half-maximal GH stimulation — was 214 nmol/L, with a maximal GH production rate of 694 mIU/L/h. Critically, ipamorelin at all dose levels stimulated GH without measurably affecting cortisol or prolactin in that study, distinguishing it from earlier GHRPs like GHRP-6 that showed meaningful cortisol-elevating effects. This cortisol-sparing profile was one of ipamorelin's key differentiating characteristics in the GH secretagogue literature.

Important context: these are IV infusion doses in a controlled PK setting, not subcutaneous injection doses. Subcutaneous bioavailability is typically lower than IV and introduces absorption-phase kinetics that the 1999 study wasn't designed to model. For researchers working with Ipamorelin 5mg, the PK data provides useful mechanistic context but doesn't directly translate to subcutaneous dosing parameters.

AOD-9604: From Obese Mouse Models to Human Clinical Trials

AOD-9604 is a modified fragment of human growth hormone (hGH176-191) that retains hGH's lipolytic activity without the growth-promoting or insulin-desensitizing effects of the full molecule. In obese mouse models, chronic intraperitoneal administration at doses around 250 µg/kg/day produced significant reductions in adipose tissue mass. The mechanism was linked to upregulation of β3-adrenergic receptor expression in adipose tissue — the receptor subtype most associated with lipolysis and thermogenesis.

What makes AOD-9604 stand apart in the peptide research field is that it progressed into human clinical trials with meaningful sample sizes — something most research peptides never achieve. A 12-week randomized trial enrolled approximately 300 obese patients across five clinical sites, testing six dose levels from placebo to 30 mg/day oral administration. The 1 mg/day group showed the most weight loss, averaging 2.8 kg versus 0.8 kg in the placebo group over 12 weeks. The 1 mg/day dose outperformed all higher doses tested — consistent with a hormetic dose-response curve rather than a linear one. Cholesterol profiles improved modestly, and the frequency of impaired glucose tolerance decreased in that dose group.

The oral route is notable because peptides typically require injection due to proteolytic degradation in the gut. AOD-9604's stability as an oral preparation in those trials provides interesting data for researchers thinking about administration routes. The compound's mechanism — specifically through β3-adrenergic receptor upregulation rather than insulin signaling disruption — gives it a differentiated profile from general metabolic peptides. AOD-9604 5mg is available for in vitro and preclinical research in lipolytic and metabolic contexts.

Epithalon: Long-Term Animal Protocols and What They Used

Anisimov, Khavinson, and colleagues at the NN Petrov Research Institute published a detailed long-term mouse study in Biogerontology (2003) using Epithalon at 1.0 µg/mouse (approximately 30–40 µg/kg) administered subcutaneously on 5 consecutive days each month. The study ran from age 3 months until natural death across 54 mice per group — a genuine lifetime administration protocol that's rarely seen in peptide research because of the time and cost involved.

That specific protocol — subcutaneous, monthly 5-day cycles, at approximately 30–40 µg/kg — is the context in which the published outcomes were observed. Maximum lifespan increased 12.3% compared to controls. Chromosome aberrations in bone marrow cells decreased 17.1%. Leukemia incidence was inhibited six-fold. These effects emerged from that very specific, very long-term administration pattern. Extrapolating from monthly 5-day subcutaneous cycles in mice to other routes, frequencies, or schedules requires genuine caution and additional research to support.

For researchers investigating Epithalon's telomere and longevity mechanisms, Epithalon 10mg is available. The dose used in Anisimov's published work — approximately 30–40 µg/kg monthly — is the best-documented reference point in the existing literature.

Comparing Routes of Administration: What Changes and What Doesn't

Route of administration matters enormously in peptide research — perhaps more than dose magnitude alone. Intraperitoneal (IP) injection in rodents delivers compounds directly to the peritoneal cavity, where they're absorbed through the mesenteric circulation and reach the portal vein quickly. Bioavailability via IP is typically higher than subcutaneous and much higher than oral for most peptides.

Oral administration works for some peptides — BPC-157 and AOD-9604 both have published oral efficacy data — but requires either extraordinary stability in gastric acid (BPC-157 is native to gastric juice and stable there) or a formulation strategy protecting the compound from proteolysis. Most peptides degrade rapidly in the GI tract, making oral data somewhat compound-specific rather than generalizable.

Subcutaneous injection is the most commonly used route in human research applications. The subcutaneous route is slower to peak plasma concentration than IV or IP, but produces more sustained exposure at lower peak concentrations. In Teichman's CJC-1295 study, subcutaneous administration was the route used, making that data directly relevant to subcutaneous research protocols. For BPC-157 animal studies that used IP, a route adjustment consideration applies when designing subcutaneous protocols.

Reading Dose Data Critically: Common Errors and How to Avoid Them

A few principles worth holding onto when interpreting dose data in the peptide literature:

• Always identify the route of administration before interpreting a dose. A 10 µg/kg IP dose is not equivalent to a 10 µg/kg subcutaneous dose in terms of bioavailability or peak plasma concentration.
• Dose-response curves for peptides are often non-linear. BPC-157's nanogram-range efficacy in some gut models is genuinely unusual — most pharmacological agents show monotonic dose-response relationships. The wide effective range warrants reading multiple studies across dose levels, not just the highest ones.
• Short-term efficacy studies and long-term safety studies ask different questions. Most peptide animal work covers 1–4 week treatment windows with endpoint-specific measurements. Extrapolating these to long-term applications requires careful consideration of what the study was actually designed to test.
• Human PK data from the Teichman CJC-1295 study is the most rigorous dosing reference available for any GHRH analog. It characterized pharmacokinetics, not efficacy optimization. The ipamorelin PK/PD modeling gave mechanistic information about receptor pharmacology. AOD-9604's clinical trial data is the most useful for understanding dose-response in a human weight management context.

The published literature on peptide dosing is more nuanced — and in some ways more conservative — than commonly circulated protocols suggest. Engaging with the primary papers, applying allometric scaling where appropriate, and understanding the distinction between pharmacokinetic and efficacy data are the foundations of sound peptide research methodology.